Perspectives
4.5-year study finds diabetes and related drug costs surging
April 1, 2016Nearly 1 in 10 Americans have diabetes.1 It’s an epidemic, and it doesn’t appear to be stopping any time soon. By 2050, as many as 1 in 3 adults in the United States will have diabetes.2
The growing diabetic population is having a marked impact on drug use and spend. Coupled with drug price inflation, rising use has led to mounting costs for plan sponsors. To help measure the impact of rising use and costs, the health outcomes team dove deep into Prime’s data to study diabetes prevalence, incidence and drug therapy.
What we studied
Prime’s research team studied nearly 4 million commercial members who were continuously enrolled in a plan for 4.5 years. We used criteria to identify members who had diabetes-related claims, and broke the data down further by diabetes (Type 1 or Type 2) and therapy type.
What we learned
Diabetes drug use and costs are rising quickly. From January 2011 to June 2015:
- The average cost for all diabetes drugs increased 168 percent.
- Diabetes drugs, as a category, increased from 6.7 percent to 10.7 percent of total drug spend.
- Insulin costs increased 200 percent, and use increased 50 percent.
- Insulin costs rose from 3 percent to 5.4 percent of total drug spend.
What plan sponsors can do
Programs such as step therapy can help plan sponsors encourage the use of generics with known, long-term safety and efficacy, resulting in lower overall drug spend. In addition, programs that help drive adherence by identifying and communicating gaps in care (such as Prime’s GuidedHealth® program) can help improve safety and outcomes, helping members get the medicines they need to live well and lowering the total cost of care.
References
- Statistics about diabetes. American Diabetes Association. (2012.) http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.com/
- Fast facts – data and statistics about diabetes. American Diabetes Association. (2012.) http://professional.diabetes.org/content/fast-facts-data-and-statistics-about-diabetes/?loc=dorg_statistics
Related news
Perspectives
November 29, 2023
Traditional Drug Pipeline Monthly Update: November 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
November 29, 2023
Specialty Drug Pipeline Monthly Update: November 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
November 16, 2023
2023 NHCAA Rewind – The Prime/MRx Special Investigations Unit is Prepped to Explore the Frontier of Fraud
Earlier this month, the Prime Therapeutics/Magellan Rx (Prime/MRx) Special Investigations Unit (SIU) and…